Rinsho Shinkeigaku (Clinical Neurology)

Symposium 4

Management of chronic migraine in Japan

Yuka Watanabe, M.D., Ph.D.1), Ryotaro Takashima, M.D., Ph.D.1), Hisatake Iwanami, M.D., Ph.D.1), Shiho Suzuki, M.D., Ph.D.1), Hisaka Igarashi, M.D., Ph.D.2) and Koichi Hirata, M.D., Ph.D.1)

1)Department of Neurology, Dokkyo Medical University
2)Fujitsu Healthcare Center and Fujitsu Hospital

The Japanese Headache Society and the Japanese Society of Neurology has published the 2013 guidelines for the diagnosis and treatment of chronic headache. A new CQ has been set up in the guidelines on the topic of "How to treat chronic migraine." In the past, lomerizine was the only prophylactic medication of migraine that was eligible under insurance coverage. However, afterward in 2010, valproate was added to the list of antimigraine medications approved under insurance coverage, followed by propranolol, amitriptyline, and verapamil, with rapid advances in the treatment of migraine. Valproate, topiramate (not approved under insurance coverage until date), and amitriptyline could potentially be used in the treatment of chronic migraine in Japan; further, considering the clinical outcomes thus far, lomerizine could also be added to the list. As a drug for migraine prophylaxis, valproate is contraindicated in pregnant women and needs to be used with caution.
Full Text of this Article in Japanese PDF (644K)

(CLINICA NEUROL, 53: 1228|1230, 2013)
key words: chronic migraine, valproate, guideline, pregnant women, contraindication

(Received: 1-Jun-13)